

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 August 2003 (21.08.2003)

PCT

(10) International Publication Number
WO 03/068757 A1

(51) International Patent Classification⁷: **C07D 239/42**,
213/73, 401/04, 405/04, 409/04, A61K 31/505, A61P 3/10

(21) International Application Number: PCT/EP03/01107

(22) International Filing Date: 5 February 2003 (05.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02003114.2 13 February 2002 (13.02.2002) EP

(71) Applicant: **F. HOFFMANN-LA ROCHE AG** [CH/CH];
Grenzacherstrasse 124, CH-4070 Basel (CH).

(72) Inventors: **BOEHRINGER, Markus**; Dachsweg 4,
CH-4313 Moehlin (CH). **LOEFFLER, Bernd, Michael**;
Seilhof 21, 79206 Oberrimsingen (DE). **PETERS,**
Jens-Uwe; Bertlingen 14, 79639 Grenzach-Wyhlen (DE).
STEGER, Matthias; Engweg 3, CH-8006 Zuerich (CH).
WEISS, Peter; Rosentalstrasse 52, CH-4058 Basel (CH).

(74) Agent: **BRODBECK, Michel**; Grenzacherstrasse 124,
CH-4070 Basel (CH).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU,
ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,
SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/068757 A1

(54) Title: NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES



(i)

(57) Abstract: The present invention relates to compounds of formula (I), wherein R¹, R², R³, R⁴ and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.

A process for the production and for the winding of
polyester multi-filament yarns as well as
the polyester multi-filament yarns obtainable by said method
and a device for the winding of one or more multi-filament yarns

Technical field:

The present invention relates to a process for the spinning and winding of polyester multi-filament yarns, which consist, in the amount of at least 90 weight %, in relation to the total weight of the polyester filament, of polybutylene terephthalate (PBT) and/or polytrimethylene terephthalate (PTMT), preferably of PTMT, as well as the polyester multi-filament yarns which can be obtained by means of the process and a device for the winding of one or more multi-filament yarns.

Background Art:


The production of continuous polyester multi-filament yarns, particularly polyethylene terephthalate (PET) multi-filament yarns, in a two-stage process, is already known. In this, multi-filament yarns are spun and wound during the first stage, which multi-filament yarns are, during a second stage, stretched into finished form and thermofixed, or else stretch-textured into bulky multi-filament yarns. Between the two stages, the packages of the multi-filament yarns can be long-term stored and transported at elevated temperatures without any influence on the process conditions of the second texturing stage and the quality of the products.

The textbook "Synthetic Filaments" by F. Fourné (1995), published by Hanser-Verlag, Munich in German, provides a general overview of this field by describing the main principles underlying the spinning and winding technology. However, in contrast to PET multi-filament yarns, polytrimethylene terephthalate (PTMT) or polybutylene terephthalate (PBT) multi-filament yarns have a

- 1 -

Novel Pyridin- and Pyrimidin-Derivatives

The present invention is concerned with pyridin- and pyrimidin-derivatives, their manufacture and their use as medicaments. In particular, the invention relates to compounds of the formula (I)



5

wherein

X is N or C-R⁵;

R¹ and R² are independently hydrogen or lower alkyl;

10 R³ is heterocyclyl; heterocyclyl mono-, di-, or tri-substituted, independently, by lower alkyl, perfluoro-lower alkyl, amino, lower alkoxy or halogen; aryl; or aryl mono-, di-, or tri-substituted, independently, by halogen, lower alkyl, amino, lower alkoxy or perfluoro-lower alkyl;

15 R⁴ is lower alkyl; lower alkoxy; lower alkylthio; heterocyclyl; heterocyclyl mono-, di-, or tri-substituted, independently, by lower alkyl, lower alkoxy, perfluoro-lower alkyl, amino or halogen; aryl; aryl mono-, di-, or tri-substituted, independently, by lower alkyl, lower alkoxy, halogen, amino, or perfluoro-lower alkyl; aryloxy lower alkyl or cycloalkyl;

R⁵ is hydrogen or lower alkyl;

and pharmaceutically acceptable salts thereof.

The enzyme dipeptidyl peptidase IV (EC.3.4.14.5, abbreviated in the following as DPP-IV) is involved in the regulation of the activities of several hormones. In particular DPP-IV is degrading efficiently and rapidly glucagon like peptide 1 (GLP-1), which is one of the most potent stimulator of insulin production and secretion. Inhibiting DPP-IV would potentiate the effect of endogenous GLP-1, and lead to higher plasma insulin concentrations. In patients suffering from impaired glucose tolerance and type 2 diabetes mellitus, higher plasma insulin concentration would moderate the dangerous hyperglycaemia and accordingly reduce the risk of tissue damage. Consequently, DPP-IV inhibitors have been suggested as drug candidates for the treatment of impaired glucose tolerance and type 2 diabetes mellitus (e.g. Vilhauer, WO98/19998). Other related state of the art can be found in WO 99/38501, DE 19616486, DE 19834591, WO 01/40180, WO 01/55105, US 6110949, WO 00/34241 and US6011155.

We have found novel DPP-IV inhibitors that very efficiently lower plasma glucose levels. Consequently, the compounds of the present invention are useful for the treatment and/or prophylaxis of diabetes, particularly non-insulin dependent diabetes mellitus, and/or impaired glucose tolerance, as well as other conditions wherein the amplification of action of a peptide normally inactivated by DPP-IV gives a therapeutic benefit. Surprisingly, the compounds of the present invention can also be used in the treatment and/or prophylaxis of obesity, Bowel disease, Colitis Ulcerosa, Morbus Crohn, and/or metabolic syndrome. Furthermore, the compounds of the present invention can be used as diuretic agents and for the treatment and/or prophylaxis of hypertension. Unexpectedly, the compounds of the present invention exhibit improved therapeutic and pharmacological properties compared to other DPP IV inhibitors known in the art, such as e.g. in context with pharmacokinetics and bioavailability.

Unless otherwise indicated, the following definitions are set forth to illustrate and define the meaning and scope of the various terms used to describe the invention herein.

In this specification the term "lower" is used to mean a group consisting of one to six, preferably of one to four carbon atom(s).

The term "halogen" refers to fluorine, chlorine, bromine and iodine, with fluorine, bromine and chlorine being preferred. Most preferred halogen is chlorine.

The term "alkyl", alone or in combination with other groups, refers to a branched or straight-chain monovalent saturated aliphatic hydrocarbon radical of one to twenty carbon atoms, preferably one to sixteen carbon atoms, more preferably one to ten carbon atoms. The term "lower alkyl", alone or in combination with other groups, refers to a branched or straight-chain monovalent alkyl radical of one to six carbon atoms, preferably

one to four carbon atoms. This term is further exemplified by radicals such as methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, isobutyl, t-butyl, n-pentyl, 3-methylbutyl, n-hexyl, 2-ethylbutyl and the like. Preferable lower alkyl residues are methyl and ethyl, with methyl being especially preferred.

- 5 The term "perfluoro-lower alkyl" refers to a lower alkyl group wherein all of the hydrogens of the lower alkyl group are substituted or replaced by fluoro. Among the preferred perfluoro-lower alkyl groups are trifluoromethyl, pentafluoroethyl and heptafluoropropyl, with trifluoromethyl being especially preferred.

- 10 The term "alkoxy" refers to the group R'-O-, wherein R' is alkyl. The term "lower-alkoxy" refers to the group R'-O-, wherein R' is lower-alkyl. Examples of lower alkoxy groups are e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy and hexyloxy, with methoxy being especially preferred.

The term "lower alkylthio" refers to the group R'-S-, wherein R' is lower-alkyl as defined above.

- 15 The term "cycloalkyl" refers to a monovalent carbocyclic radical of three to six, preferably three to five carbon atoms. This term is further exemplified by radicals such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, with cyclopropyl being preferred.

- 20 The term "heterocyclyl" refers to a saturated, unsaturated or aromatic monovalent 5- to 7-membered monocyclic, 9-membered bicyclic or 13-membered tricyclic radical having at least one heteroatom selected from nitrogen, sulfur and oxygen, or a combination thereof. Examples of heterocyclyl residues are pyridyl, pyrimidinyl, furyl, thienyl, indolyl, benzo[1,3]dioxolyl, benzofuranyl, benzothiophenyl, dibenzofuranyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, oxatriazolyl, thiatrizolyl, pyridazyl, pyrimidinyl, pyrazinyl, pyrrolidinyl, azepanyl, and
25 morpholino. Said heterocyclyl residues may be mono-, di- or tri-substituted, independently, by halogen, amino, perfluoro-lower alkyl, lower alkyl or lower alkoxy, preferably by lower alkyl or lower alkoxy.

- 30 The term "aryl" refers to an aromatic monovalent mono- or polycarbocyclic radical, such as phenyl and naphthyl, preferably phenyl, which may optionally be mono-, di- or tri-substituted, independently, by lower alkyl, lower alkoxy, halogen, amino or perfluoro-lower alkyl, preferably by lower alkyl, lower alkoxy and halogen.

The term "aryloxy lower alkyl" refers to an aryl residue as defined above attached to a lower alkylene group via an oxy radical, i.e. aryl-O-R, wherein R is lower alkylene.

The term "pharmaceutically acceptable salts" embraces salts of the compounds of formula (I) with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid, phosphoric acid, citric acid, formic acid, maleic acid, acetic acid, fumaric acid, succinic acid, tartaric acid, methanesulphonic acid, salicylic acid, p-toluenesulphonic acid and the like, which are non toxic to living organisms. Preferred salts with acids are formates, maleates, citrates, hydrochlorides, hydrobromides and methanesulfonic acid salts, with hydrochlorides being especially preferred.

In one embodiment of the present invention, R^1 is lower alkyl, with methyl and isopropyl being preferred. In a preferable embodiment, R^1 is hydrogen.

10 In another embodiment of the present invention, R^2 is lower alkyl, with methyl being preferred. In a preferable embodiment, R^2 is hydrogen.

In one embodiment of the present invention, X is N. In another embodiment, X is C- R^5 . Preferable X is N.

In one embodiment, R^3 is heterocyclyl, such as pyridyl, pyrimidinyl, furyl, thienyl, indolyl, benzo[1,3]dioxolyl, benzofuranyl, benzothiophenyl, dibenzofuranyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, oxatriazolyl, thiatriazolyl, pyridazyl, pyrazinyl, pyrrolidinyl, azepanyl and morpholino, which heterocyclyl residues may optionally mono-, di- or tri-substituted, independently, by lower alkyl, lower alkoxy, perfluoro-lower alkyl, amino or halogen, preferably by lower alkyl, lower alkoxy or halogen. Preferred heterocyclyl residues R^3 are unsubstituted thienyl and unsubstituted benzo[1,3]dioxolyl. In a preferable embodiment, R^3 is aryl, preferably phenyl, optionally *ortho*-, *meta*- and/or *para*-, preferably *ortho*- and *para*- substituted, independently, by lower alkyl, lower alkoxy, halogen, amino or perfluoro-lower alkyl, preferably by halogen, lower alkyl, perfluoro-lower alkyl or lower alkoxy. Most preferable residue R^3 is 2,4-dichloro-phenyl.

In one embodiment, R^4 is aryl such as phenyl or naphthyl, with phenyl being preferred. Phenyl residues R^4 may optionally be *ortho*-, *meta*- and/or *para*-substituted, independently, by halogen, amino, lower alkyl, perfluoro-lower alkyl or lower alkoxy, preferably by halogen, such as fluoro, by lower alkyl, such as methyl or lower alkoxy, such as methoxy. Naphthyl residues R^4 are preferably unsubstituted or mono-substituted by lower alkoxy, such as methoxy. In another embodiment R^4 is lower alkoxy, preferably methoxy. In still another embodiment R^4 is lower alkyl. Preferable lower alkyl residues R^4 are methyl and isopropyl. In another embodiment R^4 is cycloalkyl, with cyclopropyl being preferred. In another embodiment R^4 is lower alkylthio, preferably methylthio. In another

embodiment R^4 is heterocyclyl. Preferable heterocyclyl residues R^4 are pyridyl, pyrimidinyl, furyl, thienyl, indolyl, benzo[1,3]dioxolyl, benzofuranyl, benzothiophenyl, dibenzofuranyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, oxatriazolyl, thiatriazolyl, pyridazyl, 5 pyrimidinyl, pyrazinyl, pyrrolidinyl, azepanyl, and morpholino. More preferable are pyridyl, thienyl, indolyl, benzo[1,3]dioxolyl, benzofuranyl, benzothiophenyl, dibenzofuranyl, pyrrolidinyl, azepanyl and morpholino. The said heterocyclyl residues may optionally be mono-, di- or tri-substituted, preferably mono- or di-substituted, independently, by halogen, amino, perfluoro-lower alkyl, lower alkyl or lower alkoxy, 10 preferably by lower alkyl or lower alkoxy. In still another embodiment, R^4 is aryloxy lower alkyl. Preferable aryloxy lower alkyl is phenoxy lower alkyl, wherein the phenyl moiety is substituted by halogen. Most preferable aryloxy lower alkyl is 4-fluorophenoxymethyl.

In one embodiment of the present invention, R^5 is lower alkyl, with methyl being preferred. In another embodiment, R^5 is hydrogen.

15 Preferred compounds in accordance with the present invention are those compounds of formula I, wherein X is N, R^1 and R^2 are hydrogen, R^3 is an aryl residue as defined above, preferably a phenyl residue which is *ortho*- and *para*-substituted, independently, by lower alkyl, lower alkoxy, halogen, amino or perfluoro-lower alkyl, most preferably 2,4-dichloro-phenyl, and R^4 is alkoxy, preferably methoxy, alkylthio, preferably 20 methylthio, aryl, preferably a phenyl residue which may optionally be *ortho*-, *meta*- and/or *para*-substituted, independently, as defined above, preferably by halogen, such as fluoro, by lower alkyl, such as methyl or lower alkoxy, such as methoxy, or a heterocyclyl residue as defined above, preferably pyrrolidinyl or azepanyl.

Compounds of formula (I) represent a preferred embodiment of the present 25 invention and pharmaceutically acceptable salts of compounds of formula (I) individually also represent a preferred embodiment of the present invention.

Preferred compounds of general formula (I) are those selected from the group consisting of:

- 5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-phenyl-pyrimidin-4-ylamine,
- 30 5-Aminomethyl-2-phenyl-6-*p*-tolyl-pyrimidin-4-ylamine,
- 5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3-methoxy-phenyl)-pyrimidin-4-ylamine,
- 5-Aminomethyl-2-phenyl-6-*o*-tolyl-pyrimidin-4-ylamine,

- 5-Aminomethyl-6-(2,4-difluoro-phenyl)-2-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-m-tolyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3,4,5-trimethoxy-phenyl)-
pyrimidin-4-ylamine,
5 5-Aminomethyl-6-(2,4-dimethyl-phenyl)-2-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3,5-dimethoxy-phenyl)-pyrimidin-
4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3-fluoro-phenyl)-pyrimidin-4-
ylamine,
10 5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(4-fluoro-phenyl)-pyrimidin-4-
ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(4-methoxy-1-methyl-1H-indol-6-
yl)-pyrimidin-4-ylamine,
5-Aminomethyl-2-benzofuran-2-yl-6-(2,4-dichloro-phenyl)-pyrimidin-4-
15 ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(1H-indol-2-yl)-pyrimidin-4-
ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-m-tolyl-pyrimidin-4-ylamine,
2-(4-Amino-3-methoxy-phenyl)-5-aminomethyl-6-(2,4-dichloro-phenyl)-
20 pyrimidin-4-ylamine,
5-Aminomethyl-2-azepan-1-yl-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3,4-difluoro-phenyl)-pyrimidin-4-
ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-pyrrolidin-1-yl-pyrimidin-4-ylamine,
25 5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-methylsulfanyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3,4-dimethoxy-phenyl)-pyrimidin-
4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-thiophen-2-yl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(2-fluoro-phenyl)-pyrimidin-4-
30 ylamine,
5-Aminomethyl-2-(4-chloro-phenyl)-6-(2,4-dichloro-phenyl)-pyrimidin-4-
ylamine,

- 5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-methoxy-pyrimidin-4-ylamine,
5-Aminomethyl-2-cyclopropyl-6-phenyl-pyrimidin-4-ylamine
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-p-tolyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(4-methoxy-phenyl)-pyrimidin-4-ylamine,
5-Aminomethyl-2-benzo[1,3]dioxol-5-yl-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3-trifluoromethyl-phenyl)-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-morpholin-4-yl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(4-trifluoromethyl-phenyl)-pyrimidin-4-ylamine,
5-Aminomethyl-2-(3-chloro-phenyl)-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-methyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-naphthalen-2-yl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-naphthalen-1-yl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3-methoxy-phenyl)-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3,5-difluoro-phenyl)-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(2-methoxy-phenyl)-pyrimidin-4-ylamine,
5-Aminomethyl-6-(4-ethyl-phenyl)-2-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-isopropyl-pyrimidin-4-ylamine,
5-Aminomethyl-2-(2-chloro-4-fluoro-phenyl)-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine,
5-Aminomethyl-2-benzo[b]thiophen-2-yl-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine,

- 5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(6-methoxy-naphthalen-2-yl)-pyrimidin-4-ylamine,
- 5-Aminomethyl-2-phenyl-6-m-tolyl-pyrimidin-4-ylamine,
- 5-Aminomethyl-6-(4-chloro-phenyl)-2-phenyl-pyrimidin-4-ylamine,
- 5 5-Aminomethyl-2-phenyl-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-ylamine,
- 5-Aminomethyl-6-(2-methoxy-phenyl)-2-phenyl-pyrimidin-4-ylamine,
- 5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-o-tolyl-pyrimidin-4-ylamine,
- 5-Aminomethyl-2-(3,5-bis-trifluoromethyl-phenyl)-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine,
- 10 5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(4-fluoro-phenoxy-methyl)-pyrimidin-4-ylamine,
- 5-Aminomethyl-6-(2-chloro-phenyl)-2-phenyl-pyrimidin-4-ylamine,
- 5-Aminomethyl-6-(2-bromo-phenyl)-2-phenyl-pyrimidin-4-ylamine,
- 5-Aminomethyl-2-dibenzofuran-2-yl-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine,
- 15 5-Aminomethyl-6-(2,4-bis-trifluoromethyl-phenyl)-2-phenyl-pyrimidin-4-ylamine,
- 5-Aminomethyl-6-(2-fluoro-4-methoxy-phenyl)-2-phenyl-pyrimidin-4-ylamine,
- 5-Aminomethyl-6-(2,4-dimethoxy-phenyl)-2-phenyl-pyrimidin-4-ylamine,
- 20 5-Aminomethyl-2-(1H-indol-2-yl)-6-phenyl-pyrimidin-4-ylamine,
- 5-Aminomethyl-6-benzo[1,3]dioxol-5-yl-2-cyclopropyl-pyrimidin-4-ylamine,
- 5-Aminomethyl-6-(2-fluoro-phenyl)-2-phenyl-pyrimidin-4-ylamine,
- 5-Aminomethyl-2-phenyl-6-(2-trifluoromethyl-phenyl)-pyrimidin-4-ylamine,
- 5-Aminomethyl-2-benzofuran-2-yl-6-phenyl-pyrimidin-4-ylamine,
- 25 5-Aminomethyl-6-(4-fluoro-phenyl)-2-phenyl-pyrimidin-4-ylamine,
- 5-Aminomethyl-2-(3,4-dimethoxy-phenyl)-6-phenyl-pyrimidin-4-ylamine,
- 5-Aminomethyl-6-phenyl-2-pyridin-4-yl-pyrimidin-4-ylamine,
- 5-Aminomethyl-6-(3-chloro-phenyl)-2-phenyl-pyrimidin-4-ylamine,
- 5-Aminomethyl-6-phenyl-2-thiophen-2-yl-pyrimidin-4-ylamine,
- 30 5-Aminomethyl-6-(3-fluoro-phenyl)-2-phenyl-pyrimidin-4-ylamine,


- 5-Aminomethyl-2,6-diphenyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(4-methoxy-phenyl)-2-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-2-phenyl-6-thiophen-3-yl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(3-methoxy-phenyl)-2-phenyl-pyrimidin-4-ylamine,
5 6-(2,4-Dichloro-phenyl)-5-methylaminomethyl-2-phenyl-pyrimidin-4-ylamine,
3-Aminomethyl-4-(2,4-dichloro-phenyl)-6-phenyl-pyridin-2-ylamine,
3-Aminomethyl-4-(2,4-dichloro-phenyl)-5-methyl-6-phenyl-pyridin-2-ylamine,
[5-Aminomethyl-6-(4-chloro-phenyl)-2-pyridin-3-yl-pyrimidin-4-yl]-methyl-
amine,
10 5-Aminomethyl-6-benzo[1,3]dioxol-5-yl-2-(4-methoxy-phenyl)-pyrimidin-4-
ylamine,
5-Aminomethyl-6-benzo[1,3]dioxol-5-yl-2-phenyl-pyrimidin-4-ylamine,
[5-Aminomethyl-6-(4-chloro-phenyl)-2-pyridin-3-yl-pyrimidin-4-yl]-isopropyl-
amine,
15 (5-Aminomethyl-2,6-diphenyl-pyrimidin-4-yl)-methyl-amine,
3-Aminomethyl-4-(4-chloro-phenyl)-5-methyl-6-phenyl-pyridin-2-ylamine,
3-Aminomethyl-4-(4-chloro-phenyl)-6-phenyl-pyridin-2-ylamine,
3-Aminomethyl-4,6-bis-(4-fluoro-phenyl)-pyridin-2-ylamine, and
3-Aminomethyl-4-benzo[1,3]dioxol-5-yl-6-phenyl-pyridin-2-ylamine,
20 and pharmaceutically acceptable salts thereof.

Compounds of formula I wherein X is C-R⁵, R⁵ is lower alkyl and R³ is ortho-substituted phenyl can exist in the form of optically pure enantiomers or as racemates. The invention embraces all of these forms.


- It will be appreciated, that the compounds of general formula (I) in this invention
25 may be derivatised at functional groups to provide derivatives which are capable of
conversion back to the parent compound in vivo.

The compounds of the present invention can be prepared as outlined in Reaction Schemes I and II below:

Reaction Scheme I



Reaction Scheme II



5

The present invention also relates to a process for the manufacture of compounds of formula I. This process comprises the reduction of nitriles of formulae IV, IVa, IX and IXa to amines of formulae Ia and Ic, respectively. This reduction can be performed according to methods known in the art. For example, the reduction can be carried out using a metal
 10 hydride such as lithium aluminum hydride in an inert solvent.

Nitriles of formulae IV and IVa are known in the art or can be prepared from arylidene malononitriles of formula V and amidines VII by processes known in the art. For example, the reaction can be performed in the presence of a base such as potassium carbonate in an inert solvent such as methanol.

- 5 Nitriles of formula IX and IXa are known in the art or can be prepared by processes known in the art. One such process is the reaction of arylidene malononitriles of formula V and ketones of formula X. For example, the reaction can be performed by heating with ammonium acetate in an inert solvent such as methanol.

- 10 Arylidene malononitriles of formula V are known in the art or can be prepared by processes known in the art, for instance by reaction of aromatic aldehydes VI with malononitrile in the presence of a base such as piperidine.

Amidines of formula VII are known in the art or can be prepared by processes known in the art. For instance, amidines of formula VII can be prepared from nitriles VIII by a process known in the art as the Pinner reaction.

- 15 Compounds of formulae Ib and Id can be prepared from corresponding compounds of formulae Ia and Ic, respectively, by an alkylation process known in the art (Bar-Haim, G.; Kol, M. Tetrahedron Lett. 1998, 39, 2663).

The invention further relates to compounds of formula (I) as defined above, when manufactured according to a process as defined above.

- 20 As described above, the compounds of formula (I) of the present invention can be used as medicaments for the treatment and/or prophylaxis of diseases which are associated with DPP IV such as diabetes, particularly non-insulin dependent diabetes mellitus, impaired glucose tolerance, Bowel disease, Colitis Ulcerosa, Morbus Crohn, obesity, and/or metabolic syndrome, preferably non-insulin dependent diabetes mellitus and/or impaired
25 glucose tolerance. Furthermore, the compounds of the present invention can be used as diuretic agents or for the treatment and/or prophylaxis of hypertension.

The invention therefore also relates to pharmaceutical compositions comprising a compound as defined above and a pharmaceutically acceptable carrier and/or adjuvant.

- 30 Further, the invention relates to compounds as defined above for use as therapeutic active substances, particularly as therapeutic active substances for the treatment and/or prophylaxis of diseases which are associated with DPP IV such as diabetes, particularly non-insulin dependent diabetes mellitus, impaired glucose tolerance, Bowel disease, Colitis Ulcerosa, Morbus Crohn, obesity, and/or metabolic syndrome, preferably for use as

therapeutic active substances for the treatment and/or prophylaxis of non-insulin dependent diabetes mellitus and/or impaired glucose tolerance. Furthermore, the invention relates to compounds as defined above for use as diuretic agents or for use as therapeutic active substances for the treatment and/or prophylaxis of hypertension.

- 5 In another embodiment, the invention relates to a method for the treatment and/or prophylaxis of diseases which are associated with DPP IV such as diabetes, particularly non-insulin dependent diabetes mellitus, impaired glucose tolerance, Bowl disease, Colitis Ulcerosa, Morbus Crohn, obesity, and/or metabolic syndrome, preferably for the treatment and/or prophylaxis of non-insulin dependent diabetes mellitus and/or impaired
10 glucose tolerance, which method comprises administering a compound as defined above to a human being or animal. Furthermore, the invention relates to a method for the treatment and/or prophylaxis as defined above, wherein the disease is hypertension or wherein a diuretic agent has a beneficial effect.

- The invention further relates to the use of compounds as defined above for the
15 treatment and/or prophylaxis of diseases which are associated with DPP IV such as diabetes, particularly non-insulin dependent diabetes mellitus, impaired glucose tolerance, Bowl disease, Colitis Ulcerosa, Morbus Crohn, obesity, and/or metabolic syndrome, preferably for the treatment and/or prophylaxis of non-insulin dependent diabetes mellitus and/or impaired glucose tolerance. Furthermore, the invention relates to the use
20 as defined above, wherein the disease is hypertension or to the use as diuretic agent.

- In addition, the invention relates to the use of compounds as defined above for the preparation of medicaments for the treatment and/or prophylaxis of diseases which are associated with DPP IV such as diabetes, particularly non-insulin dependent diabetes mellitus, impaired glucose tolerance, Bowl disease, Colitis Ulcerosa, Morbus Crohn,
25 obesity, and/or metabolic syndrome, preferably for the treatment and/or prophylaxis of non-insulin dependent diabetes mellitus and/or impaired glucose tolerance. Such medicaments comprise a compound as defined above. Furthermore, the invention relates to the use as defined above, wherein the disease is hypertension or the use for the preparation of diuretic agents.

- 30 In context with the methods and uses defined above, the following diseases relate to a preferred embodiment: diabetes, particularly non-insulin dependent diabetes mellitus, impaired glucose tolerance, obesity, and/or metabolic syndrome, preferably non-insulin dependent diabetes mellitus and/or impaired glucose tolerance.

- The compounds of formula (I) can be manufactured by the methods given below, by
35 the methods given in the Examples or by analogous methods. Appropriate reaction

conditions for the individual reaction steps are known to the person skilled in the art. Starting materials are either commercially available or can be prepared by methods analogous to the methods given below or in the Examples or by methods known in the art.

5 The following tests were carried out in order to determine the activity of the compounds of formula I.

Activity of DPP-IV inhibitors are tested with natural human DPP-IV derived from a human plasma pool or with recombinant human DPP-IV. Human citrate plasma from different donors is pooled, filtered through a 0.2 micron membrane under sterile conditions and aliquots of 1 ml are shock frozen and stored at -120°C until used. In the colorimetric DPP-IV assay 5 to 10 μl human plasma and in the fluorometric assay 1.0 μl of human plasma in a total assay volume of 100 μl is used as an enzyme source. The cDNA of the human DPP-IV sequence of amino acid 31 – to 766, restricted for the N-terminus and the transmembrane domain, is cloned into pichia pastoris. Human DPP-IV is expressed and purified from the culture medium using conventional column chromatography including size exclusion and anion and cation chromatography. The purity of the final enzyme preparation of Coomassie blue SDS-PAGE is $> 95\%$. In the colorimetric DPP-IV assay 20 ng rec.-h DPP-IV and in the fluorometric assay 2 ng rec.-h DPP-IV in a total assay volume of 100 μl is used as an enzyme source.

In the fluorogenic assay Ala-Pro-7-amido-4-trifluoromethylcoumarin (Calbiochem No 125510) is used as a substrate. A 20 mM stock solution in 10 % DMF/ H_2O is stored at -20°C until use. In IC_{50} determinations a final substrate concentration of 50 μM is used. In assays to determine kinetic parameters as K_m , V_{max} , K_i , the substrate concentration is varied between 10 μM and 500 μM .

In the colorimetric assay H-Ala-Pro-pNA.HCl (Bachem L-1115) is used as a substrate. A 10 mM stock solution in 10% MeOH/ H_2O is stored at -20°C until use. In IC_{50} determinations a final substrate concentration of 200 μM is used. In assays to determine kinetic parameters as K_m , V_{max} , K_i , the substrate concentration is varied between 100 μM and 2000 μM .

Fluorescence is detected in a Perkin Elmer Luminescence Spectrometer LS 50B at an excitation wavelength of 400 nm and an emission wavelength of 505 nm continuously every 15 seconds for 10 to 30 minutes. Initial rate constants are calculated by best fit linear regression.

The absorption of pNA liberated from the colorimetric substrate is detected in a Packard SpectraCount at 405 nm continuously every 2 minutes for 30 to 120 minutes. Initial rate constants are calculated by best fit linear regression.

DPP-IV activity assays are performed in 96 well plates at 37°C in a total assay volume of 100 µl. The assay buffer consists of 50 mM Tris/HCl pH 7.8 containing 0.1 mg/ml BSA and 100 mM NaCl. Test compounds are solved in 100 % DMSO; diluted to the desired concentration in 10% DMSO/H₂O. The final DMSO concentration in the assay is 1 %
5 (v/v). At this concentration enzyme inactivation by DMSO is < 5%. Compounds are with (10 minutes at 37°C) and without preincubation with the enzyme. Enzyme reactions are started with substrate application followed by immediate mixing.

IC₅₀ determinations of test compounds are calculated by non-linear best fit regression of the DPP-IV inhibition of at least 5 different compound concentrations. Kinetic parameters
10 of the enzyme reaction are calculated at at least 5 different substrate concentrations and at least 5 different test compound concentrations.

The preferred compounds of the present invention exhibit IC₅₀ values of 1 nM to 10 µM, more preferably of 1 - 100 nM, as shown in the following table:

Example	IC ₅₀ [µM]
76	0.391
13	0.0002
12	0.0001
23	0.013
20	0.003
43	0.389
11	0.172
16	0.0007
79	0.873

15

The compounds of formula I and/or their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical preparations for enteral, parenteral or topical administration. They can be administered, for example, perorally, e.g.

in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions, rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions or infusion solutions, or topically, e.g. in the form of ointments, creams or oils. Oral administration is preferred.

5 The production of the pharmaceutical preparations can be effected in a manner which will be familiar to any person skilled in the art by bringing the described compounds of formula I and/or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible
10 solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.

Suitable carrier materials are not only inorganic carrier materials, but also organic carrier materials. Thus, for example, lactose, corn starch or derivatives thereof, talc, stearic acid or its salts can be used as carrier materials for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carrier materials for soft gelatine capsules are, for example,
15 vegetable oils, waxes, fats and semi-solid and liquid polyols (depending on the nature of the active ingredient no carriers might, however, be required in the case of soft gelatine capsules). Suitable carrier materials for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar and the like. Suitable carrier materials for injection solutions are, for example, water, alcohols, polyols, glycerol and vegetable oils.
20 Suitable carrier materials for suppositories are, for example, natural or hardened oils, waxes, fats and semi-liquid or liquid polyols. Suitable carrier materials for topical preparations are glycerides, semi-synthetic and synthetic glycerides, hydrogenated oils, liquid waxes, liquid paraffins, liquid fatty alcohols, sterols, polyethylene glycols and cellulose derivatives.

25 Usual stabilizers, preservatives, wetting and emulsifying agents, consistency-improving agents, flavour-improving agents, salts for varying the osmotic pressure, buffer substances, solubilizers, colorants and masking agents and antioxidants come into consideration as pharmaceutical adjuvants.

The dosage of the compounds of formula I can vary within wide limits depending on
30 the disease to be controlled, the age and the individual condition of the patient and the mode of administration, and will, of course, be fitted to the individual requirements in each particular case. For adult patients a daily dosage of about 1 to 1000 mg, especially about 1 to 100 mg, comes into consideration. Depending on severity of the disease and the precise pharmacokinetic profile the compound could be administered with one or several
35 daily dosage units, e.g. in 1 to 3 dosage units.

The pharmaceutical preparations conveniently contain about 1-500 mg, preferably 1-100 mg, of a compound of formula I.

The following Examples serve to illustrate the present invention in more detail. They are, however, not intended to limit its scope in any manner.

Examples

Abbreviations:

MS = mass spectrometry, aq = aqueous, r.t. = room temperature, THF = tetrahydrofuran, TFA = trifluoroacetic acid, NMR = nuclear magnetic resonance spectroscopy, DMF =
5 dimethylformamide, DMSO = dimethylsulfoxide, DCM = dichloromethane.

Example 1

Synthesis of aryl methylidene malononitriles
(Procedure 1 in Reaction Scheme I)

10 2-(2,4-Dichloro-benzylidene)-malononitrile

Under an atmosphere of argon, 2,4-dichlorobenzaldehyde (30.00g, 171mmol) and malononitrile (13.59g, 206mmol) were suspended in 1-butanol (350ml). After stirring for 15min, 8 drops of piperidine were added at room temperature. After stirring for an additional 3h, diethyl ether was added. The precipitate was filtered and washed with
15 diethyl ether and hexane to give the title compound, MS: $m/e = 222.8$ (M^+), as a colorless solid (35.34g, 92%).

$^1\text{H-NMR}$ (300MHz, d^6 -DMSO, 25°C): δ (ppm) = 7.45 (1H, m), 7.59 (1H, m), 8.18 (2H, m).

The following methylidene malononitriles were prepared in analogy to the procedure
20 described above:

2-(4-Trifluoromethyl-benzylidene)-malononitrile, MS: $m/e = 222.9$ (M^+), was prepared from 4-trifluoromethyl benzaldehyde as a solid (1.35g, 48%).

2-(2-Methyl-benzylidene)-malononitrile, MS: $m/e = 168.8$ (M^+), was prepared from *ortho*-tolyl aldehyde as a solid (1.99g, 73%).

25 2-(3-Methoxy-benzylidene)-malononitrile, MS: $m/e = 184.7$ (M^+), was prepared from *meta*-anisaldehyde as a solid (1.71g, 55%).

2-(2,4-Dimethoxy-benzylidene)-malononitrile, MS: $m/e = 214.8$ (M^+), was prepared from 2,4-dimethoxybenzaldehyde as a solid (2.48g, 96%).

2-(2,4-Dimethyl-benzylidene)-malononitrile, MS: $m/e = 182.8$ (M^+), was prepared from 2,4-dimethylbenzaldehyde as a solid (1.75g, 63%).

2-(2-Fluoro-4-methoxy-benzylidene)-malononitrile, MS: $m/e = 202.7$ (M^+), was prepared from 2-fluoro-4-methoxybenzaldehyde as a solid (1.56g, 64%).

- 5 2-(2,4-Difluoro-benzylidene)-malononitrile, MS: $m/e = 190.7$ (M^+), was prepared from 2,4-difluorobenzaldehyde as a solid (2.38g, 96%).

2-(4-Fluoro-benzylidene)-malononitrile, MS: $m/e = 172.8$ (M^+), was prepared from 4-fluorobenzaldehyde as a solid (1.87g, 84%).

- 10 2-(2-Bromo-benzylidene)-malononitrile, MS: $m/e = 233.8$ (M^+), was prepared from 2-bromobenzaldehyde as a solid (1.59g, 57%).

2-(2,4-Bis-trifluoromethyl-benzylidene)-malononitrile, MS: $m/e = 290.7$ (M^+), was prepared from 2,4-bis(trifluoromethyl)benzaldehyde as a solid (1.10g, 92%).

2-(2-Fluoro-benzylidene)-malononitrile, MS: $m/e = 172.9$ (M^+), was prepared from 2-fluorobenzaldehyde as a solid (1.55g, 75%).

- 15 2-Thiophen-3-ylmethylene-malononitrile was prepared from 3-thiophenecarbaldehyde as a solid (0.4g, 21%).

2-(3-Fluoro-benzylidene)-malononitrile, MS: $m/e = 160.8$ (M^+), was prepared from 3-fluorobenzaldehyde as a solid (1.72g, 83%).

- 20 2-(3-Methyl-benzylidene)-malononitrile, MS: $m/e = 168.7$ (M^+), was prepared from m-tolylaldehyde as a solid (0.74g, 37%).

2-(2-Trifluoromethyl-benzylidene)-malononitrile, MS: $m/e = 222.8$ (M^+), was prepared from 2-trifluoromethylbenzaldehyde as a solid (2.20g, 83%).

2-Benzo[1,3]dioxol-5-ylmethylene-malononitrile, MS: $m/e = 189.8$ (M^+), was prepared from piperonal as a solid (19.4g, 98%).

- 25 2-(4-Methyl-benzylidene)-malononitrile, MS: $m/e = 168.9$ (M^+), was prepared from 4-methylbenzaldehyde as a solid.

2-(4-Chloro-benzylidene)-malononitrile, MS: $m/e = 188.7$ (M^+), was prepared from 4-chlorobenzaldehyde as a solid.

2-(2-Methoxy-benzylidene)-malononitrile, MS: $m/e = 184.8$ (M^+), was prepared from 2-methoxybenzaldehyde as a solid.

2-(2-Chloro-benzylidene)-malononitrile, MS: $m/e = 188.9$ (M^+), was prepared from 2-chlorobenzaldehyde as a solid.

5 2-(3-Chloro-benzylidene)-malononitrile, MS: $m/e = 188.9$ (M^+), was prepared from 3-chlorobenzaldehyde as a solid.

2-(4-Methoxy-benzylidene)-malononitrile, MS: $m/e = 184.7$ (M^+), was prepared from 4-methoxybenzaldehyde as a solid.

10 2-Thiophen-3-ylmethylene-malononitrile, MS: $m/e = 160.8$ (M^+), was prepared from 3-thiophenecarbaldehyde as a solid.

2-(3-Methoxy-benzylidene)-malononitrile, MS: $m/e = 184.8$ (M^+), was prepared from 3-methoxybenzaldehyde as a solid.

Example 2

15 Synthesis of Benzamidines (Procedure 2 in Reaction Scheme I)

3,5-Dimethoxy-benzamidine

Dry HCl gas was bubbled through a cooled (-15°C) solution of 3,5-dimethoxybenzonitrile (1.50g, 9.20mmol) for 30 minutes. The reaction mixture was placed in a refrigerator
20 overnight. After evaporation of the solvent, a white solid was obtained which was dissolved in ethanol. 9.2ml of a 2molar solution of ammonia in Methanol was added and the reaction mixture was stirred at room temperature overnight. After evaporation of the solvent, the title compound, MS: $m/e = 181.2$ ($M+H^+$), (1.21g, 71%) was obtained by chromatographic purification of the residue (silica gel, MeOH, DCM).

25 $^1\text{H-NMR}$ (300MHz, $d^6\text{-DMSO}$, 25°C): $\delta(\text{ppm}) = 3.80$ (6H, s), 6.82 (1H, t, $J = 2\text{Hz}$), 7.05 (2H, t, $J = 2\text{Hz}$), 9.35 (3H, bs).

The following benzamidines were prepared in analogy to the procedure described above:

3-Trifluoromethyl-benzamidine, MS: $m/e = 189.2$ ($M+H^+$), was prepared from 3-trifluoromethyl-benzonitrile as a solid (1.14g, 69%).

2-Methoxy-benzamidine, MS: $m/e = 151.2$ ($M+H^+$), was prepared from 2-methoxybenzonitrile as a solid (113mg, 7%).

3,4,5-Trimethoxy-benzamidine, MS: $m/e = 211.3$ ($M+H^+$), was prepared from 3,4,5-trimethoxy-benzaldehyde as a solid.

- 5 3,4 -Dimethoxy-benzamidine, MS: $m/e = 181.2$ ($M+H^+$), was prepared from 3,4-dimethoxy-benzaldehyde as a solid.

Thiophene-2-carboxamidine, MS: $m/e = 127.1$ ($M+H^+$), was prepared from thiophene-3-carbonitrile as a solid.

- 10 2-Fluorobenzamidine, MS: $m/e = 139.2$ ($M+H^+$), was prepared from 2-fluorobenzonitrile as a solid.

4-Chlorobenzamidine, MS: $m/e = 154.2$ ($M+H^+$), was prepared from 4-chlorobenzonitrile as a solid.

4-Methylbenzamidine, MS: $m/e = 135.1$ ($M+H^+$), was prepared from 4-methylbenzonitrile as a solid.

- 15 4-Methoxybenzamidine, MS: $m/e = 151.3$ ($M+H^+$), was prepared from 4-methoxybenzonitrile as a solid.

Benzo[1,3]dioxole-5-carboxamidine, MS: $m/e = 165.2$ ($M+H^+$), was prepared from benzo[1,3]dioxole-5-carbonitrile as a solid.

- 20 Naphthalene-1-carboxamidine, MS: $m/e = 171.2$ ($M+H^+$), was prepared from naphthalene-1-carbonitrile as a solid.

3-Methoxy-benzamidine, MS: $m/e = 151.3$ ($M+H^+$), was prepared from 3-methoxybenzonitrile as a solid.

2-Chloro-4-fluorobenzamidine, MS: $m/e = 173.1$ ($M+H^+$), was prepared from 3-chloro-4-fluorobenzonitrile as a solid.

- 25 2-Methylbenzamidine, MS: $m/e = 134.1$ ($M+H^+$), was prepared from 2-methylbenzonitrile as a solid.

1*H*-indole-2-carboxamidine, MS: $m/e = 160.2$ ($M+H^+$), was prepared from 1*H*-indole-2-carbonitrile as a solid.

Benzofuran-2-carboxamidine, MS: $m/e = 161.3$ ($M+H^+$), was prepared from benzofuran-2-carbonitrile as a solid.

Isonicotinamidine, MS: $m/e = 122.2$ ($M+H^+$), was prepared from 4-cyanopyridine as a solid.

5

Example 3

Synthesis of 4-Amino-pyrimidine-5-carbonitriles (Procedure 3 in Reaction Scheme I)

4-Amino-6-(2,4-dichloro-phenyl)-2-phenyl-pyrimidine-5-carbonitrile

- 10 Potassium carbonate (4.34g, 31.4mmol) and benzamidine (2.59g, 21.5mmol) were added to a suspension of 2-(2,4-dichloro-benzylidene)-malononitrile (4g, 17.9mmol) in methanol. The yellow mixture was stirred for 1h at room temperature and then heated to reflux for an additional 2 h. After cooling, the solvent was removed at reduced pressure, the residue was taken up in ethyl acetate/ice. The organic phase was separated, washed
- 15 with water, and dried over sodium sulfate. The solvent was evaporated, the orange residue was taken up in acetone, and 1.91g potassium manganate was added. After stirring for 90min, the reaction mixture was filtered through decalite and evaporated. Purification by flash chromatography (silica gel, EtOAc / hexanes) afforded the title compound, MS: $m/e = 340.8$ (M^+), as a solid (2.63g, 43%).
- 20 $^1\text{H-NMR}$ (300MHz, d^6 -DMSO, 25°C): $\delta(\text{ppm}) = 7.48\text{-}7.60$ (3H, m), 7.62-7.68 (2H, m), 7.77 (1H, s), 8.30 (2H, bs), 8.60-8.70 (2H, m).

The following 4-Amino-pyrimidine-5-carbonitriles were prepared in analogy to the procedure described above:

- 25 4-Amino-6-benzo[1,3]dioxol-5-yl-2-phenyl-pyrimidine-5-carbonitrile, MS: $m/e = 315.9$ (M^+), was prepared from 2-benzo[1,3]dioxol-5-ylmethylene-malononitrile as a solid (629mg, 23%).

4-Amino-6-benzo[1,3]dioxol-5-yl-2-(4-methoxy-phenyl)-pyrimidine-5-carbonitrile, MS: $m/e = 346.2$ (M^+), was prepared from 2-benzo[1,3]dioxol-5-ylmethylene-malononitrile and *p*-Methoxybenzamidine as a solid (78mg, 26%).

4-Amino-2-phenyl-6-(4-trifluoromethyl-phenyl)-pyrimidine-5-carbonitrile, MS: $m/e = 340.1$ (M^+), was prepared from 2-(4-trifluoromethyl-benzylidene)-malononitrile as a solid (312mg, 20%).

5 4-Amino-2-phenyl-6-*o*-tolyl-pyrimidine-5-carbonitrile, MS: $m/e = 286.8$ ($M+H^+$), was prepared from 2-(2-methyl-benzylidene)-malononitrile as a solid (700mg, 22%).

4-Amino-6-(3-methoxy-phenyl)-2-phenyl-pyrimidine-5-carbonitrile, MS: $m/e = 301.8$ (M^+), was prepared from 2-(3-methoxy-benzylidene)-malononitrile as a solid (391mg, 15%).

10 4-Amino-2-phenyl-6-*m*-tolyl-pyrimidine-5-carbonitrile, MS: $m/e = 286.1$ (M^+), was prepared from 2-(3-methyl-benzylidene)-malononitrile as a solid (515mg, 28%).

4-Amino-2-phenyl-6-*p*-tolyl-pyrimidine-5-carbonitrile, MS: $m/e = 286.0$ (M^+), was prepared from 2-(4-methyl-benzylidene)-malononitrile as a solid (3.13g, 37%).

15 4-Amino-6-(2,4-dichloro-phenyl)-2-(3-methoxy-phenyl)-pyrimidine-5-carbonitrile, MS: $m/e = 371.2$ ($M+H^+$), was prepared from 2-(2,4-dichloro-benzylidene)-malononitrile and 3-methoxybenzamidine as a solid (17mg, 32%).

4-Amino-6-(2,4-difluoro-phenyl)-2-phenyl-pyrimidine-5-carbonitrile was prepared from 2-(2,4-difluoro-benzylidene)-malononitrile as a solid (430mg, 88%).


20 4-Amino-6-(2,4-dichloro-phenyl)-2-*m*-tolyl-pyrimidine-5-carbonitrile, MS: $m/e = 308.1$ (M^+), was prepared from 2-(2,4-dichloro-benzylidene)-malononitrile and 3-methylbenzamidine as a solid (150mg, 87%).

4-Amino-6-(2,4-dichloro-phenyl)-2-(3,4,5-trimethoxy-phenyl)-pyrimidine-5-carbonitrile, MS: $m/e = 430.0$ (M^+), was prepared from 2-(2,4-dichloro-benzylidene)-malononitrile and 3,4,5-trimethoxy-benzamidine as a solid (1.4g, 96%).

Example 4

Synthesis of 5-Aminomethyl-pyrimidin-4-ylamines
(Procedure 4 in Reaction Scheme I)

5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-phenyl-pyrimidin-4-ylamine




5

Under an atmosphere of argon, a solution of 4-Amino-6-(2,4-dichloro-phenyl)-2-phenyl-pyrimidine-5-carbonitrile (1.16g, 0.34mmol) in THF (6ml) was added slowly to a suspension of LiAlH_4 in THF (3ml). After stirring for 2h at 40°C, the reaction mixture was cooled to -20°C and water (0.6ml) was added. After 15min, ethyl acetate was added and the mixture was filtered through Decalite. The organic phase was then separated, washed with water, and dried over sodium sulfate. Purification by flash chromatography (silica gel, methanol, dichloromethane) afforded the title compound, MS: $m/e = 344.2$ (M^+), as a light yellow solid (0.446g, 40%).

$^1\text{H-NMR}$ (300MHz, $\text{d}^6\text{-DMSO}$, 25°C): $\delta(\text{ppm}) = 3.35$ (1H, d, $J = 11\text{Hz}$), 3.50 (1H, d, $J = 11\text{Hz}$), 7.28 (bs, 2H), 7.38-7.46 (3H, m), 7.50-7.58 (2H, m), 7.75 (1H, m), 8.20-8.30 (2H, m).

15

Example 5


5-Aminomethyl-2-phenyl-6-*p*-tolyl-pyrimidin-4-ylamine

20

The title compound, MS: $m/e = 289.9$ (M^+), was prepared from 4-amino-2-phenyl-6-*p*-tolyl-pyrimidine-5-carbonitrile in analogy to the process described in Example 4 as a solid (190mg, 37%).


Example 6

5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3-methoxy-phenyl)-pyrimidin-4-ylamine



The title compound, MS: $m/e = 374.9 (M^+)$, was prepared from 4-amino-6-(2,4-dichloro-phenyl)-2-(3-methoxy-phenyl)-pyrimidine-5-carbonitrile in analogy to the process described in Example 4 as a solid (1.5mg, 9%).


Example 7

5-Aminomethyl-2-phenyl-6-*o*-tolyl-pyrimidin-4-ylamine

The title compound, MS: $m/e = 290.8 (M+H^+)$, was prepared from 4-amino-2-phenyl-6-*o*-tolyl-pyrimidine-5-carbonitrile in analogy to the process described in Example 4 as a solid (62mg, 31%).

Example 8

5-Aminomethyl-6-(2,4-difluoro-phenyl)-2-phenyl-pyrimidin-4-ylamine




The title compound, MS: $m/e = 312.1$ (M^+), was prepared from 4-amino-2-phenyl-6-*o*-tolyl-pyrimidine-5-carbonitrile in analogy to the process described in Example 4 as a solid (21mg, 10%).

5

Example 9

5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-*m*-tolyl-pyrimidin-4-ylamine




The title compound, MS: $m/e = 359.1$ ($M+H^+$), was prepared from 4-amino-6-(2,4-dichloro-phenyl)-2-*m*-tolyl-pyrimidine-5-carbonitrile in analogy to the process described in Example 4 as a solid (1.4mg, 92%).

10

Example 10

5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3,4,5-trimethoxy-phenyl)-pyrimidin-4-ylamine




15

The title compound, MS: $m/e = 434.9$ (M^+), was prepared from 4-amino-6-(2,4-dichloro-phenyl)-2-(3,4,5-trimethoxy-phenyl)-pyrimidine-5-carbonitrile in analogy to the process described in Example 4 as a solid (164mg, 12%).

Example 11

5-Aminomethyl-pyrimidin-4-ylamines by high-throughput synthesis from
aryl methylidene malononitriles
(Procedure 5 in Reaction Scheme I)


5 5-Aminomethyl-6-(2,4-dimethyl-phenyl)-2-phenyl-pyrimidin-4-ylamine



Benzamidine (48mg, 0.4mmol) and potassium carbonate (97mg, 0.7mmol) were placed in a reaction vial and suspended in 2ml MeOH. 2-(2,4-dimethyl-benzylidene)-malononitrile (87mg, 0.48mmol) was added, the vial was stoppered and shaken first for 30min at r.t.,
10 then for 3h at 60°C. After cooling, the mixture was filtered and the filtrate was evaporated in a vacuum zentrifuge (45°C). The residue was dissolved in 2ml of acetone, 63mg (0.4mmol) KMnO₄ was added, and the mixture was shaken for 2h at rt. The reaction mixture was then filtered and the filtrate evaporated in a vacuum zentrifuge (45°C). Purification of the re-dissolved (DMF, 1ml) residue by automated, preparative HPLC
15 (YMC CombiPrep C18 column 50x20mm, solvent gradient 5-95% CH₃CN in 0.1% TFA(aq) over 6.0min, λ = 230nm, flow rate 40ml/min) gave 22mg of an intermediate which was dissolved in THF (1ml) and added, under an atmosphere of argon, to a cooled (0°C) suspension of 100mg of Lithium aluminim hydride in 1ml THF in a reaction vial. The raction mixture was shaken first for 2h at r.t. and subsequently for 4h at 40°C. Upon
20 cooling, water was added carefully and the mixture was filtered. The filtrate was evaporated in a vacuum zentrifuge (45°C). Purification of the re-dissolved (DMF, 1ml) residue by automated, preparative HPLC (YMC CombiPrep C18 column 50x20mm, solvent gradient 5-95% CH₃CN in 0.1% TFA(aq) over 6.0min, λ = 230nm, flow rate 40ml/min) gave 8mg (7%) of the title compound, MS: m/e = 304.9 (M⁺), as a solid.

Example 12


5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3,5-dimethoxy-phenyl)-pyrimidin-4-ylamine



The title compound, MS: $m/e = 405.4$ ($M+H^+$), was prepared from 3,5-dimethoxy-
5 benzamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process
described in Example 11 as a solid.

Example 13

5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3-fluoro-phenyl)-pyrimidin-4-ylamine




10

The title compound, MS: $m/e = 362.9$ ($M+H^+$), was prepared from 3-fluoro-benzamidine
and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in
Example 11 as a solid.

15

Example 14

5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(4-fluoro-phenyl)-pyrimidin-4-ylamine




The title compound, MS: $m/e = 362.9$ ($M+H^+$), was prepared from 4-fluoro-benzamidine
and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in

Example 11 as a solid.

Example 15


5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(4-methoxy-1-methyl-1*H*-indol-6-yl)-
pyrimidin-4-ylamine



The title compound, MS: $m/e = 428.0$ ($M+H^+$), was prepared from 4-methoxy-1-methyl-1*H*-indole-6-carboxamidinium and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

Example 16


5-Aminomethyl-2-benzofuran-2-yl-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine



The title compound, MS: $m/e = 385.3$ ($M+H^+$), was prepared from benzofuran-2-carboxamidinium and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

Example 17

5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(1*H*-indol-2-yl)-pyrimidin-4-ylamine




The title compound, MS: $m/e = 383.9$ ($M+H^+$), was prepared from 1*H*-indole-2-carboxamidinium and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

5

Example 18


5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-*m*-tolyl-pyrimidin-4-ylamine



The title compound, MS: $m/e = 359.1$ ($M+H^+$), was prepared from 3-methyl-benzamidinium and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in
10 Example 11 as a solid.

Example 19

2-(4-Amino-3-methoxy-phenyl)-5-aminomethyl-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine




15

The title compound, MS: $m/e = 389.9$ ($M+H^+$), was prepared from 4-amino-3-methoxy-benzamidinium and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

Example 20


5-Aminomethyl-2-azepan-1-yl-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine



The title compound, MS: $m/e = 366.0$ ($M+H^+$), was prepared from azepane-1-carboxamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

Example 21

5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3,4-difluoro-phenyl)-pyrimidin-4-ylamine



10

The title compound, MS: $m/e = 381.3$ ($M+H^+$), was prepared from 3,4-difluorobenzamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

15

Example 22

5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-pyrrolidin-1-yl-pyrimidin-4-ylamine



The title compound, MS: $m/e = 337.8 (M^+)$, was prepared from pyrrolidine-1-carboxamide and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

5

Example 23


5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-methylsulfanyl-pyrimidin-4-ylamine



The title compound, MS: $m/e = 315.2 (M^+)$, was prepared from 2-methyl-isothiourea and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in
10 Example 11 as a solid.

Example 24


5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3,4-dimethoxy-phenyl)-pyrimidin-4-ylamine



15 The title compound, MS: $m/e = 405.3 (M+H^+)$, was prepared from 3,4-dimethoxy-benzamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

Example 25

20 5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-thiophen-2-yl-pyrimidin-4-ylamine




The title compound, MS: $m/e = 351.2$ ($M+H^+$), was prepared from thiophene-2-carboxamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

5

Example 26

5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(2-fluoro-phenyl)-pyrimidin-4-ylamine




The title compound, MS: $m/e = 363.0$ ($M+H^+$), was prepared from 2-fluorobenzamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in

10 Example 11 as a solid.

Example 27

5-Aminomethyl-2-(4-chloro-phenyl)-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine



15 The title compound, MS: $m/e = 377.8$ (M^+), was prepared from 4-chloro-benzamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

Example 28

20

5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-methoxy-pyrimidin-4-ylamine




The title compound, , MS: $m/e = 337.8$ (M^+), was prepared from 2-methyl-isourea and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 a solid.

5

Example 29


5-Aminomethyl-2-cyclopropyl-6-phenyl-pyrimidin-4-ylamine



The title compound, MS: $m/e = 240.1$ (M^+), was prepared from cyclopropanecarboxamidine and 2-benzylidene-malononitrile in analogy to the process described in Example 11 as a solid.

10


Example 30

5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-*p*-tolyl-pyrimidin-4-ylamine

15 The title compound, MS: $m/e = 358.2$ (M^+), was prepared from 4-methylbenzamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

Example 31

20 5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(4-methoxy-phenyl)-pyrimidin-4-ylamine




The title compound, MS: $m/e = 375.3$ ($M+H^+$), was prepared from 4-methoxybenzamidinium and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

5

Example 32

5-Aminomethyl-2-benzo[1,3]dioxol-5-yl-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine




The title compound, MS: $m/e = 388.2$ (M^+), was prepared from benzo[1,3]dioxole-5-carboxamidinium and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

10

Example 33

5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3-trifluoromethyl-phenyl)-pyrimidin-4-ylamine



15

The title compound, MS: $m/e = 412.9$ ($M+H^+$), was prepared from 3-trifluoromethylbenzamidinium and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

Example 34


5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-morpholin-4-yl-pyrimidin-4-ylamine



The title compound, MS: $m/e = 353.9$ (M^+), was prepared from morpholine-4-carboxamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

Example 35


5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(4-trifluoromethyl-phenyl)-pyrimidin-4-ylamine



The title compound, MS: $m/e = 412.9$ ($M+H^+$), was prepared from 4-trifluoromethyl-benzamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

Example 36

5-Aminomethyl-2-(3-chloro-phenyl)-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine




The title compound, MS: $m/e = 378.8$ ($M+H^+$), was prepared from 3-chlorobenzamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

5

Example 37

5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-methyl-pyrimidin-4-ylamine




The title compound, MS: $m/e = 282.9$ ($M+H^+$), was prepared from acetamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

10

Example 38


5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-naphthalen-2-yl-pyrimidin-4-ylamine



15 The title compound, MS: $m/e = 394.9$ ($M+H^+$), was prepared from naphthalene-2-carboxamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

Example 39


5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-naphthalen-1-yl-pyrimidin-4-ylamine



The title compound, MS: $m/e = 395.3$ ($M+H^+$), was prepared from naphthalene-1-carboxamide and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

Example 40

5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3-methoxy-phenyl)-pyrimidin-4-ylamine




10

The title compound, MS: $m/e = 374.8$ (M^+), was prepared from 3-methoxybenzamidinium and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

Example 41


5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3,5-difluoro-phenyl)-pyrimidin-4-ylamine



The title compound, MS: $m/e = 380.9 (M+H^+)$, was prepared from 3,5-difluorobenzamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

Example 42

5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(2-methoxy-phenyl)-pyrimidin-4-ylamine




10

The title compound, MS: $m/e = 374.8 (M+H^+)$, was prepared from 2-methoxybenzamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

15

Example 43

5-Aminomethyl-6-(4-ethyl-phenyl)-2-phenyl-pyrimidin-4-ylamine



The title compound, MS: $m/e = 304.8$ ($M+H^+$), was prepared from 2-(4-ethyl-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

Example 44

- 5 5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-isopropyl-pyrimidin-4-ylamine




The title compound, MS: $m/e = 311.2$ ($M+H^+$), was prepared from isobutyramidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

10

Example 45


- 5-Aminomethyl-2-(2-chloro-4-fluoro-phenyl)-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine



- 15 The title compound, MS: $m/e = 396.8$ (M^+), was prepared from 2-chlor-4-fluoro-benzamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

Example 46

- 20 5-Aminomethyl-2-benzo[b]thiophen-2-yl-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine




The title compound, MS: $m/e = 400.9$ ($M+H^+$), was prepared from benzo[*b*]thiophene-2-carboxamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

5

Example 47

5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(6-methoxy-naphthalen-2-yl)-pyrimidin-4-ylamine




The title compound, MS: $m/e = 425.0$ ($M+H^+$), was prepared from 6-methoxy-naphthalene-2-carboxamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

10

Example 48

5-Aminomethyl-2-phenyl-6-*m*-tolyl-pyrimidin-4-ylamine




15

The title compound, MS: $m/e = 291.2$ ($M+H^+$), was prepared from 4-Amino-2-phenyl-6-*m*-tolyl-pyrimidine-5-carbonitrile in analogy to the process described in Example 11 as a solid.

20

Example 49


5-Aminomethyl-6-(4-chloro-phenyl)-2-phenyl-pyrimidin-4-ylamine



The title compound MS: $m/e = 311.0$ ($M+H^+$), was prepared from 2-(4-chloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

Example 50

5 5-Aminomethyl-2-phenyl-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-ylamine




The title compound, MS: $m/e = 344.0$ (M^+), was prepared from 2-(4-trifluoromethyl-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

10

Example 51

5-Aminomethyl-6-(2-methoxy-phenyl)-2-phenyl-pyrimidin-4-ylamine




The title compound, MS: $m/e = 306.8$ (M^+), was prepared from 2-(2-methoxy-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

15

Example 52


5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-*o*-tolyl-pyrimidin-4-ylamine



20 The title compound, MS: $m/e = 358.9$ ($M+H^+$), was prepared from 2-methyl-benzamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

Example 53

5-Aminomethyl-2-(3,5-bis-trifluoromethyl-phenyl)-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine




5

The title compound, MS: $m/e = 481.2$ ($M+H^+$), was prepared from 3,5-bis-trifluoromethyl-benzamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

10

Example 54


5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(4-fluoro-phenoxy-methyl)-pyrimidin-4-ylamine



15 The title compound, MS: $m/e = 392.8$ ($M+H^+$), was prepared from 2-(4-fluoro-phenoxy)-acetamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

Example 55


5-Aminomethyl-6-(2-chloro-phenyl)-2-phenyl-pyrimidin-4-ylamine



The title compound, MS: $m/e = 311.0$ (M^+), was prepared from 2-(2-chloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

Example 56


5-Aminomethyl-6-(2-bromo-phenyl)-2-phenyl-pyrimidin-4-ylamine



The title compound, MS: $m/e = 354.8$ (M^+), was prepared from 2-(2-bromo-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

Example 57


5-Aminomethyl-2-dibenzofuran-2-yl-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine



The title compound, MS: $m/e = 434.9$ (M^+), was prepared from dibenzofuran-2-carboxamide and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

Example 58


5-Aminomethyl-6-(2,4-bis-trifluoromethyl-phenyl)-2-phenyl-pyrimidin-4-ylamine



The title compound, MS: $m/e = 413.0$ ($M+H^+$), was prepared from 2-(2,4-bis-trifluoromethyl-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

Example 59

5-Aminomethyl-6-(2-fluoro-4-methoxy-phenyl)-2-phenyl-pyrimidin-4-ylamine




10

The title compound, MS: $m/e = 324.8$ (M^+), was prepared from 2-(2-fluoro-4-methoxy-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.


Example 60

15 5-Aminomethyl-6-(2,4-dimethoxy-phenyl)-2-phenyl-pyrimidin-4-ylamine



The title compound, MS: $m/e = 336.8$ (M^+), was prepared from 2-(2,4-dimethoxy-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.


Example 61

5-Aminomethyl-2-(1*H*-indol-2-yl)-6-phenyl-pyrimidin-4-ylamine

5 The title compound, MS: $m/e = 315.8$ ($M+H^+$), was prepared from 1*H*-indole-2-carboxamidine and 2-benzylidene-malononitrile in analogy to the process described in Example 11 as a solid.

Example 62

5-Aminomethyl-6-benzo[1,3]dioxol-5-yl-2-cyclopropyl-pyrimidin-4-ylamine



10

The title compound, MS: $m/e = 284.7$ ($M+H^+$), was prepared from cyclopropylcarboxamidine and 2-benzo[1,3]dioxol-5-ylmethylene-malononitrile in analogy to the process described in Example 11 as a solid.

15

Example 63

5-Aminomethyl-6-(2-fluoro-phenyl)-2-phenyl-pyrimidin-4-ylamine




The title compound, MS: $m/e = 294.9$ ($M+H^+$), was prepared from 2-(2-fluoro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

20

Example 64


5-Aminomethyl-2-phenyl-6-(2-trifluoromethyl-phenyl)-pyrimidin-4-ylamine



The title compound, MS: $m/e = 345.1$ ($M+H^+$), was prepared from 2-(2-trifluoromethyl-
5 benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

Example 65


5-Aminomethyl-2-benzofuran-2-yl-6-phenyl-pyrimidin-4-ylamine



10 The title compound, MS: $m/e = 316.7$ ($M+H^+$), was prepared from benzofuran-2-
carboxamidine and 2-benzylidene-malononitrile in analogy to the process described in
Example 11 as a solid.

Example 66


15 5-Aminomethyl-6-(4-fluoro-phenyl)-2-phenyl-pyrimidin-4-ylamine



The title compound, MS: $m/e = 294.8$ ($M+H^+$), was prepared from 2-(4-fluoro-
benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

Example 67


5-Aminomethyl-2-(3,4-dimethoxy-phenyl)-6-phenyl-pyrimidin-4-ylamine



The title compound, MS: $m/e = 336.8$ ($M+H^+$), was prepared from 3,4-
5 dimethoxybenzamidinium and 2-benzylidene-malononitrile in analogy to the process
described in Example 11 as a solid.

Example 68

5-Aminomethyl-6-phenyl-2-pyridin-4-yl-pyrimidin-4-ylamine




10

The title compound, MS: $m/e = 278.0$ ($M+H^+$), was prepared from isonicotinamidinium and
2-benzylidene-malononitrile in analogy to the process described in Example 11 as a solid.

Example 69

15 5-Aminomethyl-6-(3-chloro-phenyl)-2-phenyl-pyrimidin-4-ylamine



The title compound, MS: $m/e = 310.0$ ($M+H^+$), was prepared from 2-(3-chloro-
benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

Example 70


5-Aminomethyl-6-phenyl-2-thiophen-2-yl-pyrimidin-4-ylamine



The title compound, MS: $m/e = 282.8 (M+H^+)$, was prepared from thiophene-2-carboxamidine and 2-benzylidene-malononitrile in analogy to the process described in Example 11 as a solid.

Example 71

5-Aminomethyl-6-(3-fluoro-phenyl)-2-phenyl-pyrimidin-4-ylamine




10

The title compound, MS: $m/e = 294.8 (M+H^+)$, was prepared from 2-(3-fluorobenzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

Example 72

5-Aminomethyl-2,6-diphenyl-pyrimidin-4-ylamine




15

The title compound, MS: $m/e = 276.9 (M+H^+)$, was prepared from 2-benzylidene-malononitrile in analogy to the process described in Example 11 as a solid.

Example 73


5-Aminomethyl-6-(4-methoxy-phenyl)-2-phenyl-pyrimidin-4-ylamine



The title compound, MS: $m/e = 306.9$ ($M+H^+$), was prepared from 2-(4-methoxy-
5 benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.

Example 74


5-Aminomethyl-2-phenyl-6-thiophen-3-yl-pyrimidin-4-ylamine



10 The title compound, MS: $m/e = 283.0$ ($M+H^+$), was prepared from 2-thiophen-3-ylmethylene-malononitrile in analogy to the process described in Example 11 as a solid.

Example 75

5-Aminomethyl-6-(3-methoxy-phenyl)-2-phenyl-pyrimidin-4-ylamine




15

The title compound, MS: $m/e = 307.2$ ($M+H^+$), was prepared from 4-Amino-6-(3-methoxy-phenyl)-2-phenyl-pyrimidine-5-carbonitrile in analogy to the process described in Example 11 as a solid.

Example 76

(Procedure 6 in Reaction Scheme I)

6-(2,4-Dichloro-phenyl)-5-methylaminomethyl-2-phenyl-pyrimidin-4-ylamine



- 5 Under an atmosphere of argon, 9-BBN (0.348ml of a 0.5molar solution in hexane, 0.174mmol) was added to a solution of 4-amino-6-(2,4-dichloro-phenyl)-2-phenyl-pyrimidine-5-carbonitrile (60mg, 0.174mmol) in THF (1ml) and stirred for 2.5h at r.t. Potassium-*tert*-butylate (20mg, 0.174mmol) was added, followed by a drop of Methyl iodide after 10min. The mixture was stirred overnight, then ethanolamine (11mg, 10 0.174mmol) was added and the mixture was heated to 50°C for 3h. After cooling, the mixture was filtered, and the filtrate was evaporated. Purification of the re-dissolved (DMF, 1ml) residue by automated, preparative HPLC (YMC CombiPrep C18 column 50x20mm, solvent gradient 5-95% CH₃CN in 0.1% TFA(aq) over 6.0min, λ = 230nm, flow rate 40ml/min) gave the title compound, MS: m/e = 358.9 (M+H⁺), (12mg, 19%) as a 15 foam.

Example 77

Synthesis of 2-Amino-nicotinonitriles
(Procedure 7 in Reaction Scheme II)

- 20 2-Amino-4-(2,4-dichloro-phenyl)-6-phenyl-nicotinonitrile

- A mixture of 2-(2,4-dichloro-benzylidene)-malononitrile (1.125g, 5mmol), acetophenone (601mg, 5mmol), ammonium acetate (578mg, 7.5mmol), and toluene (5ml) was stirred for 3h at reflux. Upon cooling to room temperature, the mixture was taken up in ethyl acetate and extracted with satd. NaHCO₃, water, and satd. NaCl, and dried over Na₂SO₄. 25 The solvent was then evaporated and the title compound (600mg, 35%), MS: m/e = 339.5 (M+H⁺), was isolated from the residue by column chromatography (silica gel, hexanes, ethyl acetate).

^1H -NMR (300MHz, CDCl_3 , 25°C): $\delta(\text{ppm}) = 5.38$ (2H, bs), 7.13 (1H, s), 7.30-7.58 (6H, m), 7.95-8.02 (2H, m).

The following 2-amino-nicotinonitrile was prepared in analogy to the procedure described above:


- 5 2-Amino-4-(2,4-dichloro-phenyl)-5-methyl-6-phenyl-nicotinonitrile, MS: $m/e = 353.9$ ($\text{M}+\text{H}^+$), was prepared from propiophenone as a solid (425mg, 24%).

Example 78

Synthesis of 3-Aminomethyl-pyridin-2-ylamines (Procedure 8 in Reaction Scheme II)

10

3-Aminomethyl-4-(2,4-dichloro-phenyl)-6-phenyl-pyridin-2-ylamine




- Under an atmosphere of argon, a solution of 2-amino-4-(2,4-dichloro-phenyl)-6-phenyl-nicotinonitrile (580mg, 1.71mmol) in THF (2ml) is added slowly to a suspension of
- 15 LiAlH_4 (324mg, 8.52mmol) in THF (2ml). After stirring for 2h at room temperature, the reaction mixture is cooled to -20°C and water (0.4ml) is added. After 15min, ethyl acetate is added and the mixture is filtered through Decalite. The organic phase is then separated, washed with water, and dried over sodium sulfate. Purification by flash chromatography (silica gel, methanol, dichloromethane) affords the title compound, MS: $m/e = 343.8$
- 20 ($\text{M}+\text{H}^+$), as a light yellow solid (36mg, 6%).

^1H -NMR (300MHz, CDCl_3 , 25°C): $\delta(\text{ppm}) = 3.40$ (1H, d, $J = 10\text{Hz}$), 3.59 (1H, d, $J = 10\text{Hz}$), 6.49 (2H, bs), 6.90 (1H, s), 7.30-7.55 (5H, m), 7.57 (1H, s), 7.90-8.10 (2H, m)

Example 79

3-Aminomethyl-4-(2,4-dichloro-phenyl)-5-methyl-6-phenyl-pyridin-2-ylamine




The title compound, MS: $m/e = 357.9 (M^+)$, was prepared from 2-amino-4-(2,4-dichloro-phenyl)-5-methyl-6-phenyl-nicotinonitrile in analogy to the process described in Example 78 as a solid (22mg, 9%).

Example 80

High-Throughput Reduction of carbonitriles to aminomethyl compounds
(Procedure 9 in Reaction Schemes I and II)

[5-Aminomethyl-6-(4-chloro-phenyl)-2-pyridin-3-yl-pyrimidin-4-yl]-methyl-amine




High-Throughput Reduction of carbonitriles to aminomethyl compounds

4-(4-Chlorophenyl)-6-(dimethylamino)-2-(3-pyridinyl)-5-pyrimidinecarbonitrile (Bionet) (50mg, 0.155mmol) was dissolved in THF (1ml) and added, under an atmosphere of argon, to a cooled (0°C) suspension of 100mg of Lithium aluminum hydride in 1ml THF in a reaction vial. The reaction mixture was shaken first for 2h at r.t. and subsequently for 4h at 40°C. Upon cooling, water was added carefully and the mixture was filtered. The filtrate was evaporated in a vacuum zentrifuge (45°C). Purification of the re-dissolved (DMF, 1ml) residue by automated, preparative HPLC (YMC CombiPrep C18 column 50x20mm, solvent gradient 5-95% CH₃CN in 0.1% TFA(aq) over 6.0min, $\lambda = 230\text{nm}$, flow rate 40ml/min) gave 17mg (34%) of the title compound, MS: $m/e = 326.0 (M+H^+)$, as a solid.

Example 81


5-Aminomethyl-6-benzo[1,3]dioxol-5-yl-2-(4-methoxy-phenyl)-pyrimidin-4-ylamine



The title compound, MS: $m/e = 351.0$ ($M+H^+$), was prepared in analogy to the process described in Example 80 from 4-amino-6-benzo[1,3]dioxol-5-yl-2-(4-methoxy-phenyl)-pyrimidine-5-carbonitrile.

Example 82


5-Aminomethyl-6-benzo[1,3]dioxol-5-yl-2-phenyl-pyrimidin-4-ylamine



The title compound, MS: $m/e = 321.0$ ($M+H^+$), was prepared in analogy to the process described in Example 80 from 4-amino-6-benzo[1,3]dioxol-5-yl-2-phenyl-pyrimidine-5-carbonitrile.

Example 83


[5-Aminomethyl-6-(4-chloro-phenyl)-2-pyridin-3-yl-pyrimidin-4-yl]-isopropyl-amine



The title compound, MS: $m/e = 354.1$ ($M+H^+$), was prepared in analogy to the process described in Example 80 from 4-(4-chlorophenyl)-6-(isopropylamino)-2-(3-pyridinyl)-5-pyrimidinecarbonitrile.

Example 84


(5-Aminomethyl-2,6-diphenyl-pyrimidin-4-yl)-methyl-amine



5 The title compound, MS: $m/e = 290.9$ ($M+H^+$), was prepared in analogy to the process described in Example 80 from 4-(methylamino)-2,6-diphenyl-5-pyrimidinecarbonitrile (Bionet).

Example 85

3-Aminomethyl-4-(4-chloro-phenyl)-5-methyl-6-phenyl-pyridin-2-ylamine




10

The title compound, MS: $m/e = 323.9$ ($M+H^+$), was prepared in analogy to the process described in Example 80 from 2-amino-4-(4-chlorophenyl)-5-methyl-6-phenylnicotinonitrile (Bionet).

15

Example 86


3-Aminomethyl-4-(4-chloro-phenyl)-6-phenyl-pyridin-2-ylamine



20 The title compound, MS: $m/e = 310.3$ ($M+H^+$), was prepared in analogy to the process described in Example 80 from 2-amino-4-(4-chlorophenyl)-6-phenylnicotinonitrile (Bionet).

Example 87

3-Aminomethyl-4,6-bis-(4-fluoro-phenyl)-pyridin-2-ylamine




The title compound, MS: $m/e = 311.9$ ($M+H^+$), was prepared in analogy to the process
5 described in Example 80 from 2-amino-4,6-bis(4-fluorophenyl)nicotinonitrile (Bionet).

Example 88

(Procedure 10 in Reaction Scheme II)

3-Aminomethyl-4-benzo[1,3]dioxol-5-yl-6-phenyl-pyridin-2-ylamine



10

2-Benzo[1,3]dioxol-5-ylmethylene-malononitrile (79mg, 0.4mmol), benzophenone
(48mg, 0.4mmol), ammonium acetate (78mg, 1.2mmol), and toluene (4ml) were placed in
a reaction vial and shaken overnight at 118°C. Upon cooling and filtration, the solution
was evaporated in a vacuum zentrifuge (45°C) and the residue was purified by automated,
15 preparative HPLC (YMC CombiPrep C18 column 50x20mm, solvent gradient 5-95%
CH₃CN in 0.1% TFA(aq) over 6.0min, $\lambda = 230\text{nm}$, flow rate 40ml/min). The obtained
solid (28mg) was dissolved in THF (1ml) and added, under an atmosphere of argon, to a
cooled (0°C) suspension of 100mg of lithium aluminum hydride in 1ml THF in a reaction
vial. The reaction mixture was shaken first for 2h at r.t. and subsequently for 4h at 40°C.
20 Upon cooling, water was added carefully and the mixture was filtered. The filtrate was
evaporated in a vacuum zentrifuge (45°C). Purification of the re-dissolved (DMF, 1ml)
residue by automated, preparative HPLC (YMC CombiPrep C18 column 50x20mm,
solvent gradient 5-95% CH₃CN in 0.1% TFA(aq) over 6.0min, $\lambda = 230\text{nm}$, flow rate
40ml/min) gave 11mg (7%) of the title compound, MS: $m/e = 320.1$ ($M+H^+$), as a solid.

Galenical Examples

Example A

Film coated tablets containing the following ingredients can be manufactured in a
5 conventional manner:

<u>Ingredients</u>	<u>Per tablet</u>	
Kernel:		
Compound of formula (I)	10.0 mg	200.0 mg
Microcrystalline cellulose	23.5 mg	43.5 mg
Lactose hydrous	60.0 mg	70.0 mg
Povidone K30	12.5 mg	15.0 mg
Sodium starch glycolate	12.5 mg	17.0 mg
Magnesium stearate	1.5 mg	4.5 mg
(Kernel Weight)	120.0 mg	350.0 mg
Film Coat:		
Hydroxypropyl methyl cellulose	3.5 mg	7.0 mg
Polyethylene glycol 6000	0.8 mg	1.6 mg
Talc	1.3 mg	2.6 mg
Iron oxyde (yellow)	0.8 mg	1.6 mg
Titan dioxide	0.8 mg	1.6 mg

The active ingredient is sieved and mixed with microcrystalline cellulose and the
mixture is granulated with a solution of polyvinylpyrrolidon in water. The granulate is
mixed with sodium starch glycolate and magesium stearate and compressed to yield
10 kernels of 120 or 350 mg respectively. The kernels are lacquered with an aq. solution /
suspension of the above mentioned film coat.

Example B

Capsules containing the following ingredients can be manufactured in a conventional manner:

<u>Ingredients</u>	<u>Per capsule</u>
Compound of formula (I)	25.0 mg
Lactose	150.0 mg
Maize starch	20.0 mg
Talc	5.0 mg

- 5 The components are sieved and mixed and filled into capsules of size 2.

Example C

Injection solutions can have the following composition:

Compound of formula (I)	3.0 mg
Polyethylene Glycol 400	150.0 mg
Acetic Acid	q.s. ad pH 5.0
Water for injection solutions	ad 1.0 ml

- 10 The active ingredient is dissolved in a mixture of polyethylene glycol 400 and water for injection (part). The pH is adjusted to 5.0 by acetic acid. The volume is adjusted to 1.0 ml by addition of the residual amount of water. The solution is filtered, filled into vials using an appropriate overage and sterilized.

Example D

Soft gelatin capsules containing the following ingredients can be manufactured in a conventional manner:

Capsule contents	
Compound of formula (I)	5.0 mg
Yellow wax	8.0 mg
Hydrogenated Soya bean oil	8.0 mg
Partially hydrogenated plant oils	34.0 mg
Soya bean oil	110.0 mg
Weight of capsule contents	165.0 mg
Gelatin capsule	
Gelatin	75.0 mg
Glycerol 85 %	32.0 mg
Karion 83	8.0 mg (dry matter)
Titan dioxide	0.4 mg
Iron oxide yellow	1.1 mg

- 5 The active ingredient is dissolved in a warm melting of the other ingredients and the mixture is filled into soft gelatin capsules of appropriate size. The filled soft gelatin capsules are treated according to the usual procedures.

Example E


- 10 Sachets containing the following ingredients can be manufactured in a conventional manner:

Compound of formula (I)	50.0 mg
Lactose, fine powder	1015.0 mg
Microcrystalline cellulose (AVICEL PH 102)	1400.0 mg
Sodium carboxymethyl cellulose	14.0 mg
Polyvinylpyrrolidon K 30	10.0 mg
Magnesium stearate	10.0 mg
Flavoring additives	1.0 mg

- 15 The active ingredient is mixed with lactose, microcrystalline cellulose and sodium carboxymethyl cellulose and granulated with a mixture of polyvinylpyrrolidon in water. The granulate is mixed with magnesium stearate and the flavouring additives and filled into sachets.

Claims

1. Compounds of formula (I)



wherein

- 5 X is N or C-R⁵;
- R¹ and R² are independently hydrogen or lower alkyl;
- R³ is heterocyclyl; heterocyclyl mono-, di-, or tri-substituted, independently, by lower
 alkyl, lower alkoxy, perfluoro-lower alkyl, amino or halogen; aryl; or aryl mono-,
 di-, or tri-substituted, independently, by halogen, lower alkyl, lower alkoxy, amino
 10 or perfluoro-lower alkyl;
- R⁴ is lower alkyl; lower alkoxy; lower alkylthio; heterocyclyl; heterocyclyl mono-, di-,
 or tri-substituted, independently, by lower alkyl, lower alkoxy, perfluoro-lower
 alkyl, amino or halogen; aryl; aryl mono-, di-, or tri-substituted, independently, by
 lower alkyl, lower alkoxy, halogen, amino, or perfluoro-lower alkyl; aryloxy lower
 15 alkyl or cycloalkyl;
- R⁵ is hydrogen or lower alkyl;
- and pharmaceutically acceptable salts thereof.

2. Compounds according to any claim 1, wherein R¹ is hydrogen.
3. Compounds according to any of claims 1 to 2, wherein R² is hydrogen.
- 20 4. Compounds according to any of claims 1 to 3, wherein X is N.
5. Compounds according to any of claims 1 to 4, wherein R³ is heterocyclyl
 selected from pyridyl, pyrimidinyl, furyl, thienyl, indolyl, benzo[1,3]dioxolyl,
 benzofuranyl, benzothiophenyl, dibenzofuranyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl,
 pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, oxatriazolyl,
 25 thiatriazolyl, pyridazyl, pyrimidinyl, pyrazinyl, pyrrolidinyl, azepanyl, and morpholino,

which heterocyclyl is optionally mono-, di- or tri-substituted, independently, by halogen, amino, perfluoro-lower alkyl, lower alkyl or lower alkoxy.

6. Compounds according to claim 5, wherein R³ is unsubstituted thienyl or unsubstituted benzo[1,3]dioxolyl.

5 7. Compounds according to any of claims 1 to 4, wherein R³ is phenyl, optionally *ortho*-, *meta*- or *para*-substituted, independently, by lower alkyl, lower alkoxy, halogen, amino or perfluoro-lower alkyl.

8. Compounds according to claim 7, wherein R³ is 2,4-dichloro-phenyl.

9. Compounds according to any of claims 1 to 8, wherein R⁴ is phenyl, optionally
10 *ortho*-, *meta*- and/or *para*-substituted, independently, by halogen, amino, lower alkyl, perfluoro-lower alkyl or lower alkoxy.

10. Compounds according to any of claims 1 to 8, wherein R⁴ is lower alkoxy.

11. Compounds according to any of claims 1 to 8, wherein R⁴ is lower alkylthio.

12. Compounds according to any of claims 1 to 8, wherein R⁴ is a heterocyclic
15 residue selected from pyridyl, thienyl, indolyl, benzo[1,3]dioxolyl, benzofuranyl, benzothiophenyl, dibenzofuranyl, pyrrolidinyl, azepanyl and morpholino, which heterocyclic residues may be mono-, di- or tri-substituted, independently, by halogen, amino, perfluoro-lower alkyl, lower alkyl or lower alkoxy.

13. Compounds according to any of claims 1 to 12, wherein X is N, R¹ and R² are
20 hydrogen, R³ is 2,4-dichloro-phenyl, and R⁴ is methoxy, methylthio, a heterocyclic residue selected from pyrrolidinyl and azepanyl, or a phenyl residue which may optionally be *ortho*-, *meta*- and/or *para*-substituted, independently, by fluoro, methyl or methoxy.

14. Compounds according to any of claims 1 to 13, wherein X is N or C-R⁵, R¹ is
hydrogen or lower alkyl, R² is hydrogen or lower alkyl, R³ is unsubstituted thienyl,
25 unsubstituted benzo[1,3]dioxolyl, or phenyl which may be *ortho*-, *meta*- and/or *para*-substituted, independently, by lower alkyl, lower alkoxy, halogen or perfluoro-lower alkyl, R⁴ is lower alkyl, lower alkoxy, lower alkylthio, C₃₋₆-cycloalkyl, heterocyclyl selected from pyridyl, thienyl, indolyl, benzo[1,3]dioxolyl, benzofuranyl, benzothiophenyl, dibenzofuranyl, pyrrolidinyl, azepanyl and morpholino, and which heterocyclyl residue
30 may be mono- or di-substituted, independently, by lower alkyl or lower alkoxy, a naphthyl residue which may be mono-substituted by lower alkoxy, a phenyl residue which may be

ortho-, *meta*- and/or *para*-substituted, independently, by halogen, amino, lower alkyl, perfluoro-lower alkyl or lower alkoxy, or phenoxy lower alkyl, wherein the phenyl moiety is substituted by halogen, and R⁵ is hydrogen or lower alkyl.

15. Compounds according to any of claims 1 to 14, selected from the group
5 consisting of:

- 5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-2-phenyl-6-p-tolyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3-methoxy-phenyl)-pyrimidin-4-ylamine,
10 5-Aminomethyl-2-phenyl-6-o-tolyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-difluoro-phenyl)-2-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-m-tolyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3,4,5-trimethoxy-phenyl)-pyrimidin-4-ylamine,
15 5-Aminomethyl-6-(2,4-dimethyl-phenyl)-2-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3,5-dimethoxy-phenyl)-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3-fluoro-phenyl)-pyrimidin-4-ylamine,
20 5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(4-fluoro-phenyl)-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(4-methoxy-1-methyl-1H-indol-6-yl)-pyrimidin-4-ylamine,
5-Aminomethyl-2-benzofuran-2-yl-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine,
25 5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(1H-indol-2-yl)-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-m-tolyl-pyrimidin-4-ylamine,
2-(4-Amino-3-methoxy-phenyl)-5-aminomethyl-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine,
30

- 5-Aminomethyl-2-azepan-1-yl-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3,4-difluoro-phenyl)-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-pyrrolidin-1-yl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-methylsulfanyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3,4-dimethoxy-phenyl)-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-thiophen-2-yl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(2-fluoro-phenyl)-pyrimidin-4-ylamine,
5-Aminomethyl-2-(4-chloro-phenyl)-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-methoxy-pyrimidin-4-ylamine,
5-Aminomethyl-2-cyclopropyl-6-phenyl-pyrimidin-4-ylamine
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-p-tolyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(4-methoxy-phenyl)-pyrimidin-4-ylamine,
5-Aminomethyl-2-benzo[1,3]dioxol-5-yl-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3-trifluoromethyl-phenyl)-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-morpholin-4-yl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(4-trifluoromethyl-phenyl)-pyrimidin-4-ylamine,
5-Aminomethyl-2-(3-chloro-phenyl)-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-methyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-naphthalen-2-yl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-naphthalen-1-yl-pyrimidin-4-

ylamine,

5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3-methoxy-phenyl)-pyrimidin-4-ylamine,

5 5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3,5-difluoro-phenyl)-pyrimidin-4-ylamine,

5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(2-methoxy-phenyl)-pyrimidin-4-ylamine,

5-Aminomethyl-6-(4-ethyl-phenyl)-2-phenyl-pyrimidin-4-ylamine,

5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-isopropyl-pyrimidin-4-ylamine,

10 5-Aminomethyl-2-(2-chloro-4-fluoro-phenyl)-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine,

5-Aminomethyl-2-benzo[b]thiophen-2-yl-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine,

15 5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(6-methoxy-naphthalen-2-yl)-pyrimidin-4-ylamine,

5-Aminomethyl-2-phenyl-6-m-tolyl-pyrimidin-4-ylamine,

5-Aminomethyl-6-(4-chloro-phenyl)-2-phenyl-pyrimidin-4-ylamine,

5-Aminomethyl-2-phenyl-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-ylamine,

5-Aminomethyl-6-(2-methoxy-phenyl)-2-phenyl-pyrimidin-4-ylamine,

20 5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-o-tolyl-pyrimidin-4-ylamine,

5-Aminomethyl-2-(3,5-bis-trifluoromethyl-phenyl)-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine,

5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(4-fluoro-phenoxy-methyl)-pyrimidin-4-ylamine,

25 5-Aminomethyl-6-(2-chloro-phenyl)-2-phenyl-pyrimidin-4-ylamine,

5-Aminomethyl-6-(2-bromo-phenyl)-2-phenyl-pyrimidin-4-ylamine,

5-Aminomethyl-2-dibenzofuran-2-yl-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine,

30 5-Aminomethyl-6-(2,4-bis-trifluoromethyl-phenyl)-2-phenyl-pyrimidin-4-ylamine,

- 5-Aminomethyl-6-(2-fluoro-4-methoxy-phenyl)-2-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dimethoxy-phenyl)-2-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-2-(1H-indol-2-yl)-6-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-benzo[1,3]dioxol-5-yl-2-cyclopropyl-pyrimidin-4-ylamine,
5 5-Aminomethyl-6-(2-fluoro-phenyl)-2-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-2-phenyl-6-(2-trifluoromethyl-phenyl)-pyrimidin-4-ylamine,
5-Aminomethyl-2-benzofuran-2-yl-6-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(4-fluoro-phenyl)-2-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-2-(3,4-dimethoxy-phenyl)-6-phenyl-pyrimidin-4-ylamine,
10 5-Aminomethyl-6-phenyl-2-pyridin-4-yl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(3-chloro-phenyl)-2-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-phenyl-2-thiophen-2-yl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(3-fluoro-phenyl)-2-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-2,6-diphenyl-pyrimidin-4-ylamine,
15 5-Aminomethyl-6-(4-methoxy-phenyl)-2-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-2-phenyl-6-thiophen-3-yl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(3-methoxy-phenyl)-2-phenyl-pyrimidin-4-ylamine,
6-(2,4-Dichloro-phenyl)-5-methylaminomethyl-2-phenyl-pyrimidin-4-ylamine,
3-Aminomethyl-4-(2,4-dichloro-phenyl)-6-phenyl-pyridin-2-ylamine,
20 3-Aminomethyl-4-(2,4-dichloro-phenyl)-5-methyl-6-phenyl-pyridin-2-ylamine,
[5-Aminomethyl-6-(4-chloro-phenyl)-2-pyridin-3-yl-pyrimidin-4-yl]-methyl-
amine,
5-Aminomethyl-6-benzo[1,3]dioxol-5-yl-2-(4-methoxy-phenyl)-pyrimidin-4-
ylamine,
25 5-Aminomethyl-6-benzo[1,3]dioxol-5-yl-2-phenyl-pyrimidin-4-ylamine,
[5-Aminomethyl-6-(4-chloro-phenyl)-2-pyridin-3-yl-pyrimidin-4-yl]-isopropyl-
amine,
(5-Aminomethyl-2,6-diphenyl-pyrimidin-4-yl)-methyl-amine,
3-Aminomethyl-4-(4-chloro-phenyl)-5-methyl-6-phenyl-pyridin-2-ylamine,

3-Aminomethyl-4-(4-chloro-phenyl)-6-phenyl-pyridin-2-ylamine,


3-Aminomethyl-4,6-bis-(4-fluoro-phenyl)-pyridin-2-ylamine, and

3-Aminomethyl-4-benzo[1,3]dioxol-5-yl-6-phenyl-pyridin-2-ylamine,

and pharmaceutically acceptable salts thereof.


- 5 16. A process for the manufacture of compounds of formula (I) as defined in any of claims 1 to 15, which process comprises:

(a) reduction of a nitrile of formulae




wherein R^1 , R^3 and R^4 are as defined in any of claims 1 to 15;

10 to an amine of formula




wherein R^1 , R^3 and R^4 are as defined in any of claims 1 to 15.

(b) reduction of a nitrile of formulae




15 wherein R^1 , R^3 , R^4 , and R^5 are as defined in any of claims 1 to 15;

to an amine of formula Ic




wherein R^1 , R^3 , R^4 , and R^5 are as defined in any of claims 1 to 15; or

(c) alkylating an amine of formula Ia




wherein R^1 , R^3 and R^4 are as defined in any of claims 1 to 15;

5 to a compound of formula Ib




wherein R^1 , R^2 , R^3 and R^4 are as defined in any of claims 1 to 15.

(d) alkylating an amine of formula Ic



10 wherein R^1 , R^3 , R^4 and R^5 are as defined in any of claims 1 to 15;

to a compound of formula Id



wherein R^1 , R^2 , R^3 , R^4 and R^5 are as defined in any of claims 1 to 15.

17. Compounds according to any of claims 1 to 15 when manufactured by a
15 process according to claim 16.

18. Pharmaceutical compositions comprising a compound according to any of
claims 1 to 15 and a pharmaceutically acceptable carrier and/or adjuvant.

19. Compounds according to any of claims 1 to 15 for use as therapeutic active substances.

20. Compounds according to any of claims 1 to 15 for use as therapeutic active substances for the treatment and/or prophylaxis of diseases which are associated with
5 DPP IV.

21. A method for the treatment and/or prophylaxis of diseases which are associated with DPP IV such as diabetes, non-insulin dependent diabetes mellitus, impaired glucose tolerance, Bowl disease, Colitis Ulcerosa, Morbus Crohn, hypertension, diseases wherein a diuretic agent has a beneficial effect, obesity, and/or metabolic
10 syndrome, which method comprises administering a compound according to any of claims 1 to 15 to a human being or animal.

22. The use of compounds according to any of claims 1 to 15 for the treatment and/or prophylaxis of diseases which are associated with DPP IV.

23. The use of compounds according to any of claims 1 to 15 for the treatment
15 and/or prophylaxis of diabetes, non-insulin-dependent diabetes mellitus, impaired glucose tolerance, Bowl disease, Colitis Ulcerosa, Morbus Crohn, hypertension, diseases wherein a diuretic agent has a beneficial effect, obesity, and/or metabolic syndrome.

24. The use of compounds according to any of claims 1 to 15 for the preparation of medicaments for the treatment and/or prophylaxis of diseases which are associated with
20 DPP IV.

25. The use of compounds according to any of claims 1 to 15 for the preparation of medicaments for the treatment and/or prophylaxis of diabetes, non-insulin-dependent diabetes mellitus, impaired glucose tolerance, Bowl disease, Colitis Ulcerosa, Morbus Crohn, hypertension, diseases wherein a diuretic agent has a beneficial effect, obesity,
25 and/or metabolic syndrome.

26. The novel compounds, processes and methods as well as the use of such compounds substantially as described hereinbefore.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/01107

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D239/42 C07D213/73 C07D401/04 C07D405/04 C07D409/04
A61K31/505 A61P3/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

CHEM ABS Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 00 61562 A (KRENITSKY PHARMA.) 19 October 2000 (2000-10-19) page 1; claims	1, 18, 19, 25
A	WO 01 64679 A (SMITHKLINE BEECHAM) 7 September 2001 (2001-09-07) claims	1, 18, 19, 25

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

6 May 2003

Date of mailing of the international search report

19/05/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Francois, J

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 26

The scope of the claim 26, is so unclear (Art. 6 PCT) that a meaningful international search is impossible with regard to this claim.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 03/01107

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 21 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 26
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 03/01107

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0061562	A	19-10-2000	AU 4331400 A	14-11-2000
			CA 2368843 A1	19-10-2000
			EP 1165523 A1	02-01-2002
			JP 2002541245 T	03-12-2002
			WO 0061562 A1	19-10-2000
<hr/>				
WO 0164679	A	07-09-2001	AU 3999201 A	12-09-2001
			EP 1265900 A1	18-12-2002
			NO 20024134 A	24-10-2002
			WO 0164679 A1	07-09-2001
<hr/>				